ABOS
Acumen Pharmaceuticals Inc
2.20$
-3.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +8.3% | -3.0% | -4.0% | -7.6% | -10.5% | -14.4% | -15.9% | -17.3% | -13.6% | +8.8% | -13.2% | |
| – | +12.8% | +3.7% | +4.3% | -22.2% | -14.1% | -13.1% | -4.2% | -11.0% | -7.5% | +8.9% | -13.2% | |
| – | -29.5% | -29.8% | +44.8% | -51.2% | +7.4% | -15.3% | +22.1% | +27.2% | +15.3% | -4.1% | +14.8% | |
| – | +13.0% | +3.7% | +3.2% | -23.1% | -14.4% | -13.1% | -3.9% | -11.7% | -7.7% | +9.9% | -14.2% | |
| – | – | -16.0% | -43.9% | +200.9% | +24.8% | -5.5% | -16.2% | +20.3% | +64.9% | +23.5% | +30.2% | |
| – | -99.9% | – | – | +18.2% | +11.2% | – | – | – | – | – | – | |
| – | – | +10.1% | -1.1% | – | – | -25.3% | -10.7% | -40.0% | -3.3% | -17.2% | +0.0% | |
| – | +607.6% | -9.8% | +15.5% | +10.7% | +14.9% | -14.4% | +12.0% | -10.5% | +6.8% | -11.9% | +27.3% | |
| – | +112.7% | -34.7% | +81.4% | +29.6% | +38.6% | -30.0% | +28.7% | -11.7% | +36.7% | -2.6% | +60.3% | |
| – | +43,200.0% | -86.0% | +3.3% | +3.2% | +3.1% | +3.8% | +2.9% | +2,536.6% | +138.1% | +61.0% | +37.6% | |
| – | +1.2% | +123.3% | +36.8% | -44.4% | +141.2% | -81.3% | +99.1% | -67.6% | -18.8% | +198.7% | +708.4% | |
| – | – | +1.0% | +1.0% | +1.0% | +1.0% | +1.1% | +3.9% | -9.5% | -17.2% | -24.4% | -29.7% | |
| – | -4.7% | -1.8% | -6.9% | -11.0% | -16.3% | -14.5% | -24.7% | -20.4% | -24.4% | +24.2% | -34.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.0% | +3.1% | +0.4% | +0.0% | -0.1% | +0.9% | +0.1% | +0.0% | 0.0% | +4.4% | +14.3% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.